首页 | 本学科首页   官方微博 | 高级检索  
     


Drug‐drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4
Authors:Andreas H. Groll  Robert Townsend  Amit Desai  Mark Jones  Marc Engelhardt  Anne‐Hortense Schmitt‐Hoffman  Roger J. M. Brüggemann
Affiliation:1. Department of Pediatric Hematology/Oncology, University Children's Hospital Münster, Münster, Germany;2. Astellas Pharma Global Development, Inc., Northbrook, IL, USA;3. Basilea Pharmaceutica International Ltd, Basel, Switzerland;4. Department of Pharmacy, Radboud University Nijmegen Medical Centre, and Centre of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands
Abstract:Patients undergoing treatment with immunosuppressant drugs following solid organ or hematopoietic stem cell transplantation are at particular risk for development of serious infections such as invasive aspergillosis. Four triazole antifungal drugs, voriconazole, posaconazole, itraconazole, and isavuconazole, are approved to treat invasive aspergillosis either as first‐ or second‐line therapy. All of these agents are inhibitors of cytochrome P450 3A4, which plays a key role in metabolizing immunosuppressant drugs such as cyclosporine, tacrolimus, and sirolimus. Thus, co‐administration of a triazole antifungal drug with these immunosuppressant drugs can potentially increase plasma concentrations of the immunosuppressant drugs, thereby resulting in toxicity, or upon discontinuation, inadvertently decrease the respective concentrations with increased risk of rejection or graft‐versus‐host disease. In this article, we review the evidence for the extent of inhibition of cytochrome P450 3A4 by each of these triazole antifungal drugs and assess their effects on cyclosporine, tacrolimus, and sirolimus. We also consider other factors affecting interactions of these two classes of drugs. Finally, we examine recommendations and strategies to evaluate and address those potential drug‐drug interactions in these patients.
Keywords:cyclosporine  invasive aspergillosis  isavuconazole  itraconazole  posaconazole  sirolimus  tacrolimus  voriconazole
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号